Search

nema

Background. Amyloidosis represents a group of different diseases characterized by extracellular accumulation of pathologic fibrillar proteins in various tissues and organs. Severe amyloid deposition in the liver parenchyma has extrahepatic involvement predominantly in the kidney or heart. We evaluated the effect of ursodeoxycholic acid, in four patients with severe hepatic amyloidosis of different etiologies, who presented with increased alkaline phosphatase and ?-glutamyl transferase. Case report. The study included four patients who presented with amyloidosis-associated intrahepatic cholestasis. Three of them had renal amyloidosis which developed 1-3 years before cholestasis occurred, the remaining one having intrahepatic cholestasis as the primary sign of the disease. Amyloidosis was identified from liver biopsies in all patients by its specific binding to Congo red and green birefringence in polarized light. The biochemical nature and the class of amyloid deposits were identified immunohistochemically. In addition to their regular treatment, the patients received 750 mg ursodeoxycholic acid per day. After 2-4 weeks all patients had a significant decrease of serum alkaline phosphatase and ?-glutamyl transferase, and their general status significantly improved. Conclusion. Treatment with ursodeoxycholic acid may be beneficial in patients with hepatic amyloidosis, and do extend indications for the use of ursodeoxycholic acid in amyloidotic cholestatic liver disease.

This study examines the relationship between erythrocyte phospholipid FA composition and insulin sensitiv­ity in obese patients on a typical Serbian diet. In 30 patients, two insulin sensitivity groups were formed and their FAs analyzed. The shares of 22:5n-3, 22:6n-3, and total n-3 PUFAs, as well as a measure of Δ5 desaturase activity (the 20:4n-6/20:3n-6 ratio) were lower in the insulin resistance group compared to the normal glucose tolerance group. The fasting insulin level and HOMA value were inversely related to the percentage of 22:5n-3, 22:6n-3, and total n-3 PUFAs. Our data indicate that the percentage of n-3 PUFAs in erythrocyte phospholipids is linked with insulin sensitivity parameters in obese patients. Masnokiselinski sastav membrana, koji se bar delimično može modifikovati dijetarnim unosom masnih kiselina, igra važnu ulogu u senzitivnosti na insulin. Cilj ove studije bio je ispitivanje veze između senzitivnosti na insulin i masnokiselinskog sastava fosfolipida eritrocita kod gojaznih osoba. Trideset umereno gojaznih/gojaznih nedijabetičara sa hiperlipoproteinemijama (ukupni holesterol gt 5.2 mmol/l, LDL-holesterol gt 3.4 mmol/l) podeljeni su u dve grupe, koristeći HOMA vrednost kao parametar senzitivnosti na insulin: grupu sa normalnom tolerancom na glukozu (NTG) i grupu sa rezistencijom na insulin (IR). Ukupni lipidi eritrocita su estrahovani i fosfolipidi izolovani tankoslojnom hromatografijom. Posle metilovanja masne kiseline analizirane su gasno-tečnom hromatografijom. Zastupljenost 22:5n-3 (p lt 0.01), 22:6n-3 (p lt 0.01), ukupnih n-3 polinezasićenih masnih kiselina (p lt 0.001) i odnos zastupljenosti 20:4n-6/20:3n-6 (pokazatelja aktivnosti delta-5 desaturaze) (p lt 0.05) su sniženi u IR grupi u poređenju sa NGT grupom. Nivo insulina natašte i HOMA vrednost inverntno su povezani sa zastupljenošću 22:5n-3 (p lt 0.05), 22:6n-3 (p lt 0.01) i ukupnim n-3 polinezasićenim kiselinama (p lt 0.01). Naši rezultati pokazuju da je nivo n-3 masnih kiselina u fosfolipidima eritrocita povezan sa senzitivnošću na insulin kod gojaznih osoba na ishrani tipičnoj za podneblje Srbije.

Background. Arterial hypertension is a multicausal chronic disease often accompanied by obesity. The aim of this investigation was to examine the effect of diet therapy in the treatment of obese hypertensives with and without antihypertensive therapy. Methods. The investigation was conducted at the Department of Nutrition on a sample of 110 obese hypertensive patients on diet therapy. Subjects were divided into two groups: the group on diet therapy with antihypertensive drugs E1 (n=78), and the group on diet therapy without pharmacotherapy E2 (n=32). Nourishment state i.e., obesity level was assessed by body mass index (BMI). All the patients belonged to the obese group - BMI > 30 kg/m2. Besides blood pressure values, the following parameters were monitored: serum cholesterol, trygliceride levels and BMI. Results. The obtained results in the group with diet therapy combined with antihypertensive therapy showed highly significant decrease of anthropometrical parameters: body weight (99.14 kg vs. 90.16 kg) (p